INmune Bio (NASDAQ:INMB) Earns Outperform Rating from Analysts at Raymond James

Research analysts at Raymond James assumed coverage on shares of INmune Bio (NASDAQ:INMB) in a note issued to investors on Friday, Marketbeat Ratings reports. The firm set an “outperform” rating and a $18.00 price target on the stock. Raymond James’ price target points to a potential upside of 244.83% from the stock’s current price.

Separately, Scotiabank initiated coverage on shares of INmune Bio in a research report on Thursday, August 22nd. They issued a “sector outperform” rating and a $22.00 price objective for the company.

INmune Bio Price Performance

NASDAQ:INMB opened at $5.22 on Friday. INmune Bio has a 1 year low of $4.81 and a 1 year high of $14.74. The stock’s fifty day moving average price is $6.73 and its two-hundred day moving average price is $8.79. The company has a market cap of $103.26 million, a P/E ratio of -2.72 and a beta of 1.86.

INmune Bio (NASDAQ:INMB) last issued its quarterly earnings data on Thursday, August 1st. The company reported ($0.50) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.63) by $0.13. INmune Bio had a negative return on equity of 103.56% and a negative net margin of 26,333.59%.

Insider Buying and Selling

In other INmune Bio news, CFO David J. Moss bought 7,690 shares of INmune Bio stock in a transaction that occurred on Thursday, September 12th. The stock was acquired at an average cost of $6.38 per share, for a total transaction of $49,062.20. Following the completion of the transaction, the chief financial officer now directly owns 1,275,869 shares in the company, valued at $8,140,044.22. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other INmune Bio news, CFO David J. Moss acquired 7,690 shares of the business’s stock in a transaction dated Thursday, September 12th. The stock was bought at an average price of $6.38 per share, with a total value of $49,062.20. Following the completion of the acquisition, the chief financial officer now owns 1,275,869 shares of the company’s stock, valued at $8,140,044.22. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Raymond Joseph Tesi acquired 15,380 shares of the firm’s stock in a transaction that occurred on Thursday, September 12th. The stock was bought at an average price of $6.38 per share, for a total transaction of $98,124.40. Following the completion of the transaction, the chief executive officer now owns 1,554,106 shares of the company’s stock, valued at approximately $9,915,196.28. The disclosure for this purchase can be found here. 35.20% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in INMB. Rhumbline Advisers bought a new stake in INmune Bio during the second quarter worth about $121,000. Fermata Advisors LLC lifted its position in INmune Bio by 8.5% in the 2nd quarter. Fermata Advisors LLC now owns 34,140 shares of the company’s stock worth $301,000 after buying an additional 2,689 shares during the last quarter. Westside Investment Management Inc. boosted its stake in INmune Bio by 31.8% in the second quarter. Westside Investment Management Inc. now owns 45,340 shares of the company’s stock worth $400,000 after buying an additional 10,950 shares in the last quarter. Bank of New York Mellon Corp grew its position in INmune Bio by 124.6% during the second quarter. Bank of New York Mellon Corp now owns 58,600 shares of the company’s stock valued at $517,000 after acquiring an additional 32,511 shares during the last quarter. Finally, Marshall Wace LLP raised its stake in shares of INmune Bio by 332.1% during the second quarter. Marshall Wace LLP now owns 115,916 shares of the company’s stock worth $1,022,000 after acquiring an additional 89,091 shares in the last quarter. 12.72% of the stock is currently owned by hedge funds and other institutional investors.

About INmune Bio

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.